Concepedia

Susan Jones‐Bolin

SJ

Statistics

Publications

13

Citations

1.4K

H-Index

12

Active since

1998

Affiliations

Johns Hopkins University(Current)

The Netherlands Cancer Institute

Fox Chase Cancer Center

Teva Pharmaceuticals (United States)

Susan Jones‐Bolin is an author at Johns Hopkins University specializing in oncology, medicine, and pharmacology.

Publications per year

1998–2012

13

Publications

13

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

Mark J. Levis, Jeffrey Allebach, Kam-Fai Tse et al. · Blood · 2002 · 474 citations

, , +11

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

Roberto Piva, Bruce Ruggeri, Michael Williams et al. · Blood · 2007 · 253 citations · Full text

, , +9

Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist

Paweł Dobrzański, Kathryn Hunter, Susan Jones‐Bolin et al. · Cancer Research · 2004 · 160 citations

, , +13

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Bruce Ruggeri, Diane E. Gingrich, Thelma S. Angeles et al. · PubMed · 2003 · 124 citations

, , +15

CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.

Christopher J. Strock, Jong‐In Park, Mark Rosen et al. · PubMed · 2003 · 94 citations

, , +17

1–5 of 13